source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
The Motley Fool | 2021-05-02 06:03:00 | https://www.fool.com/investing/2021/05/02/warren-buffetts-3-highest-yielding-dividend-stocks/ | Here's why they could be attractive to most income-seeking investors. | Warren Buffett's 3 Highest-Yielding Dividend Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-01 06:50:00 | https://www.fool.com/investing/2021/05/01/better-buy-for-2021-abbvie-or-merck/ | Which company should you consider buying right now? | Better Buy for 2021: AbbVie or Merck? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-30 16:27:00 | https://www.fool.com/investing/2021/04/30/abbvie-rises-on-q1-beats-raised-eps-guidance/ | The company is excited about its prospects for the remainder of this year. | AbbVie Rises on Q1 Beats, Raised EPS Guidance | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-04-30 15:18:09 | https://investorplace.com/2021/04/7-value-stocks-you-want-in-your-life/ | Although growth-related investments have been all the rage, smart investors should see the potential in buying value stocks. The post 7 Value Stocks You Want In Your Life appeared first on InvestorPlace. | 7 Value Stocks You Want In Your Life | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-30 15:08:04 | https://seekingalpha.com/article/4423075-abbvie-abbv-ceo-rick-gonzalez-on-q1-2021-results-earnings-call-transcript | AbbVie (ABBV) CEO, Rick Gonzalez on Q1 2021 Results - Earnings Call Transcript | AbbVie (ABBV) CEO, Rick Gonzalez on Q1 2021 Results - Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-30 12:01:20 | https://www.zacks.com/stock/news/1479453/abbvie-abbv-beats-on-q1-earnings-raises-2021-guidance | AbbVie (ABBV) beats on first-quarter 2021 earnings and revenues. Shares up in pre-market trading. | AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-30 10:35:19 | https://www.fool.com/investing/2021/04/30/how-abbvie-beat-expectations-again-in-q1/ | Humira is still the main star for now, but the company's newer drugs are gaining momentum. | How AbbVie Beat Expectations Again in Q1 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-04-30 09:17:48 | https://www.benzinga.com/news/earnings/21/04/20887535/abbvie-beats-q1-earnings-on-strong-humira-sales-raises-full-year-profit-forecast | AbbVie Inc (NYSE: ABBV) beat Wall Street consensus for first-quarter revenue & earnings and raised its full-year profit forecast, helped by demand for its rheumatoid arthritis drug, Humira, and newer treatments such as psoriasis treatment Skyrizi. It reported an adjusted EPS of $2.95, which beat the analyst consensus e... | AbbVie Beats Q1 Earnings On Strong Humira Sales, Raises Full-Year Profit Forecast | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2021-04-30 08:18:28 | https://www.marketwatch.com/story/abbvies-stock-is-up-20-as-humira-sales-top-39-billion-in-sales-in-the-first-quarter-2021-04-30 | Shares of AbbVie Inc. gained 2.0% in premarket trading on Friday after it beat earnings expectations and saw a noticeable jump in pharmaceutical revenue for the first quarter of 2021. The diagnostics company had earnings of $3.5 billion, or $1.99 earnings per share, in the first quarter of 2021, compared with $3.0 bill... | AbbVie's stock is up 2.0% as Humira sales top $3.9 billion in sales in the first quarter | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-30 08:17:00 | https://www.fool.com/investing/2021/04/30/3-warren-buffett-stocks-worth-buying-now/ | Borrow a tip from the best-known name in the stock-picking business. | 3 Warren Buffett Stocks Worth Buying Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-04-30 08:00:54 | https://www.benzinga.com/news/earnings/21/04/20886199/abbvie-q1-earnings-insights | Shares of AbbVie (NYSE:ABBV) rose 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 21.90% over the past year to $2.95, which beat the estimate of $2.83. | AbbVie: Q1 Earnings Insights | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2021-04-30 07:51:00 | https://www.reuters.com/article/us-abbvie-results/abbvie-raises-full-year-profit-forecast-as-humira-fuels-sales-beat-idUSKBN2CH1GS | AbbVie Inc beat Wall Street estimates for first-quarter revenue on Friday and raised its full-year profit forecast, helped by demand for blockbuster rheumatoid arthritis drug Humira and newer treatments such as psoriasis treatment Skyrizi. | AbbVie raises full-year profit forecast as Humira fuels sales beat | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-04-30 07:42:00 | https://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2021-financial-results-301281124.html | NORTH CHICAGO, Ill., April 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. | AbbVie Reports First-Quarter 2021 Financial Results | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-04-29 16:21:51 | https://www.gurufocus.com/news/1411391/astrazeneca-merck-abbvie-struck-biggest-licensing-deals-in-2020 | In my April 27 discussion, I looked at the pharmaceutical companies that are most likely to pursue acquisitions this year, with activity forecasted to pick up after a down 2020. While the pandemic contributed to the slowdown in merger and acquisitions, licensing arrangements fared far better, coming in relatively flat ... | AstraZeneca, Merck, AbbVie Struck Biggest Licensing Deals in 2020 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-04-29 10:16:10 | https://www.benzinga.com/news/earnings/21/04/20864994/a-preview-of-abbvies-earnings | AbbVie (NYSE:ABBV) unveils its next round of earnings this Friday, April 30. Get prepared with Benzinga's ultimate preview for AbbVie's Q1 earnings. | A Preview Of AbbVie's Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-04-29 06:00:37 | https://investorplace.com/2021/04/7-pharmaceutical-stocks-to-buy-for-valuation-plus-solid-dividends/ | High-quality pharmaceutical stocks comes with steady business, low valuations and solid dividend. Let's look at a handful of them now. | 7 Pharmaceutical Stocks To Buy For Valuation Plus Solid Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-28 17:56:57 | https://www.fool.com/investing/2021/04/28/is-abbvie-a-buy-before-its-earnings-report-friday/ | How the pharma company progresses on its pivot away from Humira will have a large impact on the stock's reaction. | Is AbbVie a Buy Before Its Earnings Report Friday? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-28 16:47:02 | https://www.zacks.com/stock/news/1468976/5-big-cap-earnings-superstars | It's not easy for companies to beat on earnings nearly every quarter for years but these five are doing it. | 5 Big Cap Earnings Superstars | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-28 13:18:06 | https://seekingalpha.com/article/4422008-update-91-top-dividend-stocks-on-earth-for-may | Kiplinger "insights for investors" online first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 4/26/21 flagged 13 yields ripe with upside. These International “Dividend Aristocrats” have raised dividends at least five straight years (Canadian), 10 years (European Union),... | Update: 91 'Top Dividend Stocks On Earth' For May | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-28 13:02:22 | https://www.zacks.com/stock/news/1467714/healthcare-etfs-on-radar-as-q1-earnings-unfold | Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns. | Healthcare ETFs on Radar As Q1 Earnings Unfold | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-28 12:17:27 | https://www.zacks.com/stock/news/1467743/strong-new-drugs-sales-to-aid-abbvies-abbv-q1-earnings | AbbVie (ABBV) is expected to have witnessed a recovery in demand trends for new drugs amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs. | Strong New Drugs Sales to Aid AbbVie's (ABBV) Q1 Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-28 12:17:17 | https://www.zacks.com/stock/news/1467601/this-is-why-abbvie-abbv-is-a-great-dividend-stock | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | This is Why AbbVie (ABBV) is a Great Dividend Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2021-04-27 17:07:07 | https://marijuanastocks.com/top-medical-marijuana-stocks-in-2021-2-for-your-may-watchlist/ | Are Medical Marijuana Stock Going To Make Investors Rich In The Future? The post Top Medical Marijuana Stocks In 2021? 2 For Your May Watchlist appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Top Medical Marijuana Stocks In 2021? 2 For Your May Watchlist | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-04-27 17:06:00 | https://www.gurufocus.com/news/1408507/top-pharma-giants-expected-to-be-most-active-in-ma | Companies likely seeking bolt-on acquisitions, not mega-deals | Top Pharma Giants Expected to Be Most Active in M&A | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-04-27 08:30:00 | https://www.prnewswire.com/news-releases/allergan-an-abbvie-company-to-share-new-data-highlighting-latest-advancements-in-eye-care-at-arvo-association-for-research-in-vision-and-ophthalmology-2021-annual-virtual-meeting-301276238.html | NORTH CHICAGO, Ill., April 27, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (Association for Research in Vision and Oph... | Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-27 06:22:00 | https://www.fool.com/investing/2021/04/27/this-pharma-giant-lost-the-vaccine-race-but-its-co/ | Its vaccine might not have panned out as expected, but Merck has more in the works. | This Pharma Giant Lost the Vaccine Race, But Its COVID-19 Journey May Not Be Over | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-26 18:17:10 | https://www.zacks.com/stock/news/1458006/abbvie-abbv-gains-but-lags-market-what-you-should-know | In the latest trading session, AbbVie (ABBV) closed at $111.39, marking a +0.01% move from the previous day. | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-24 06:04:00 | https://www.fool.com/investing/2021/04/24/3-bargain-stocks-to-buy-with-the-market-near-all-t/ | Not every stock is ridiculously expensive right now. | 3 Bargain Stocks to Buy With the Market Near All-Time Highs | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-23 10:31:19 | https://www.zacks.com/stock/news/1441726/whats-in-the-cards-for-abbvie-abbv-this-earnings-season | Higher demand for its growth drugs is likely to have offset generic competition for Humira in the United States to boost AbbVie's (ABBV) first-quarter sales. | What's in the Cards for AbbVie (ABBV) This Earnings Season? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-04-23 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-receives-positive-chmp-opinion-for-venclyxto-venetoclax-as-a-combination-regimen-for-adult-patients-with-newly-diagnosed-acute-myeloid-leukemia-who-are-ineligible-for-intensive-chemotherapy-301275874.html | NORTH CHICAGO, Ill., April 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VENCLYXTO® (venetoclax) in combination with hypomethylating agents for the treatment of adult patie... | AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-23 04:34:11 | https://seekingalpha.com/article/4420834-introduction-to-buckets-dgi-investors | Many DGI investors have goals focused on income and growing the dividend stream. Their portfolio strategy should reflect these goals. | An Introduction To 'Buckets' For DGI Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-21 09:54:29 | https://seekingalpha.com/article/4420239-abbvie-dividend-aristocrat-five-percent-yield | AbbVie is still facing extremely high debt levels and has high amounts of goodwill on its balance sheet, which should make us cautious. The company used the money mostly for acquisitions to become less dependent on Humira. | AbbVie: Dividend Aristocrat With A 5% Dividend Yield | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-21 05:45:00 | https://www.fool.com/investing/2021/04/21/3-stocks-for-a-better-retirement/ | Want dividends? How do yields of 4.8% and 5.8% sound? | 3 Stocks for a Better Retirement | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-20 08:12:00 | https://www.fool.com/investing/2021/04/20/warren-buffett-owns-these-5-dividend-aristocrats-s/ | The stock market's dividend yield is at a 10-year low, but these five companies still yield over 2%. | Warren Buffett Owns These 5 Dividend Aristocrats. Should You? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2021-04-19 18:39:00 | https://www.reuters.com/article/us-usa-opioids-litigation/jj-other-drugmakers-go-to-trial-in-california-in-50-billion-case-over-deadly-legacy-of-opioids-idUSKBN2C611N | Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive risks, a lawyer for several California counties argued on Monday at the start of multibillion-dollar trial. | J&J, other drugmakers go to trial in California in $50 billion case over 'deadly legacy' of opioids | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-19 18:27:16 | https://www.zacks.com/stock/news/1421872/abbvie-abbv-gains-as-market-dips-what-you-should-know | AbbVie (ABBV) closed at $108.61 in the latest trading session, marking a +0.65% move from the prior day. | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-18 19:58:24 | https://seekingalpha.com/article/4419694-2-fast-growing-dividend-aristocrats-for-rich-retirement | The market continues to march higher, powered by daily increases in earnings growth expectations. However, the market is now 36% historically overvalued. Over the next five years, analysts expect just 4.3% annual returns from the S&P 500. And over the next 30+ years 7.9%. The dividend aristocrats are expected to delive... | 2 Fast-Growing Dividend Aristocrats For A Rich Retirement | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-15 08:35:00 | https://seekingalpha.com/article/4418999-dividend-aristocrat-on-sale-abbvie-abbv | Some in the investment community are spooked by the upcoming loss of Humira exclusivity. Revenue will likely fall in 2023, but the acquisition of Allergan, as well as the growth of revenue from Rinvoq, Skyrizi and Imbruvica should fill the gap. | A Dividend Aristocrat On Sale: AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-14 10:54:55 | https://www.fool.com/investing/2021/04/14/got-1000-2-dirt-cheap-value-stocks-you-can-buy-rig/ | Worried about sky-high valuations? Check out these two pharma stocks. | Got $1,000? 2 Dirt-Cheap Value Stocks You Can Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-14 07:13:00 | https://www.fool.com/investing/2021/04/14/follow-warren-buffett-into-these-three-pharma-comp/ | See why the world's most acclaimed value investor is investing in these three stocks. | Follow Warren Buffett Into These 3 Pharma Companies | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-14 07:01:00 | https://www.fool.com/investing/2021/04/14/should-abbvie-be-worried-about-rinvoq/ | There's more reason to be concerned than in the past. | Should AbbVie Be Worried About Rinvoq? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-13 18:56:21 | https://www.zacks.com/stock/news/1391579/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know | AbbVie (ABBV) closed at $108.22 in the latest trading session, marking a -0.03% move from the prior day. | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-13 05:47:45 | https://seekingalpha.com/article/4418794-three-stocks-to-buy-and-hold-forever | Since the first post, Altria performed well, while AT&T and AbbVie's catalysts have yet to unlock their upside potential. | 3 More A+ Stocks To Buy And Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-13 05:12:00 | https://www.fool.com/investing/2021/04/13/2-stocks-that-are-perfect-to-buy-now-and-hold-unti/ | Their high yields and history of success bode well for the long term. | 2 Stocks That Are Perfect to Buy Now and Hold Until Retirement | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-12 12:53:21 | https://www.zacks.com/stock/news/1384871/abbvie-abbv-is-a-top-dividend-stock-right-now-should-you-buy | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-12 12:07:18 | https://www.zacks.com/stock/news/1384838/has-abbvie-abbv-outpaced-other-medical-stocks-this-year | Is (ABBV) Outperforming Other Medical Stocks This Year? | Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-11 11:19:40 | https://seekingalpha.com/article/4418523-abbvie-stock-buy-humira-fear-and-profit | AbbVie is a blue-chip pharmaceutical company that is known for its massive dividend. The company will lose exclusivity on its top selling drug in a couple of years. AbbVie has begun preparing for this (see Allergan merger). | AbbVie: Buy The Humira Fear And Profit | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-11 06:30:00 | https://www.fool.com/investing/2021/04/11/4-green-flags-for-abbvie-in-2021/ | Expect solid sales growth through the next year or two. | 4 Green Flags for AbbVie in 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-11 06:01:00 | https://www.fool.com/investing/2021/04/11/3-great-dividend-stocks-to-buy-right-now/ | These stocks check off all the boxes for dividend-seeking investors. | 3 Great Dividend Stocks to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-10 06:01:00 | https://www.fool.com/investing/2021/04/10/better-value-stock-abbvie-or-viatris/ | Look at more than just the valuation metrics. | Better Value Stock: AbbVie or Viatris? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-09 11:15:19 | https://seekingalpha.com/article/4418334-2-dividend-stocks-with-great-potential-viacomcbs-and-abbvie | ViacomCBS is the combination of CBS and Viacom that has created a media conglomerate operating around the world. AbbVie's top drug, Humira, represents over half of the company's current profits. | 2 Dividend Stocks With Great Potential: ViacomCBS And AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-08 09:05:10 | https://www.zacks.com/stock/news/1364456/abbvie-abbv-seeks-skyrizi-approval-for-psoriatic-arthritis | AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis. | AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2021-04-07 12:06:22 | https://www.forbes.com/sites/qai/2021/04/07/top-stocks-to-buy-this-month-amid-optimistic-markets/ | Netflix and Facebook are among the top stocks for April. Q.ai's Artificial Intelligence has also dug up top tech stocks, top consumer stocks, top quality value stocks, and top growth stocks. | Top Stocks To Buy This Month Amid Optimistic Markets | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-04-07 10:42:08 | https://www.benzinga.com/general/biotech/21/04/20519975/abbvie-files-us-europe-applications-for-skyrizi-in-psoriatic-arthritis | AbbVie Inc (NYSE: ABBV) has submitted marketing applications to the FDA and European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) for the treatment of adults with active psoriatic arthritis. In the Phase 3 KEEPsAKE-1 and KEEPsAKE-2 studies, Skyrizi demonstrated significant improvement... | AbbVie Files US, Europe Applications For Skyrizi In Psoriatic Arthritis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-04-07 09:01:00 | https://www.prnewswire.com/news-releases/abbvie-submits-regulatory-applications-for-skyrizi-risankizumab-in-psoriatic-arthritis-to-fda-and-ema-301264138.html | NORTH CHICAGO, Ill., April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI® (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI® (risankizumab, 150 mg) to the European Medicines Agency (EMA) for the treatm... | AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-04-07 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-data-across-its-robust-neuroscience-portfolio-at-the-2021-american-academy-of-neurology-aan-annual-meeting-301263600.html | NORTH CHICAGO, Ill., April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22. | AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-07 06:10:00 | https://www.fool.com/investing/2021/04/07/does-2021s-best-biopharma-to-work-for-belong-in-yo/ | Horizon Therapeutics has a clear path to significant sales growth. | Does 2021's Best Biopharma to Work for Belong in Your Portfolio? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-06 10:15:29 | https://seekingalpha.com/article/4417808-4-high-yield-healthcare-stocks-richly-reward-investors | Healthcare is one of the most defensive sectors and often contains strong moats. Fortunately for income investors, there are also numerous high-yield opportunities in the space. | 4 High-Yield Healthcare Stocks That Could Richly Reward Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-06 07:23:00 | https://www.fool.com/investing/2021/04/06/should-you-buy-abbvie-in-april/ | Shares of AbbVie have climbed more than 22% over the past 12 months, but there's still room to grow. | Should You Buy AbbVie in April? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-04-05 09:05:24 | https://www.zacks.com/stock/news/1348343/abbvies-abbv-rinvoq-dermatitis-snda-review-gets-delayed | The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months. | AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-04-03 07:25:00 | https://www.fool.com/investing/2021/04/03/this-is-why-big-pharma-hates-the-new-infrastructur/ | This is why America's largest pharmaceutical companies are nervous about the American Jobs Plan. | 11 Words From President Biden That Frighten Big Pharma | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-04-02 17:18:00 | https://www.prnewswire.com/news-releases/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of-upadacitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301261596.html | NORTH CHICAGO, Ill., April 2, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults... | AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-04-02 08:15:00 | https://seekingalpha.com/article/4417289-top-10-undervalued-high-yield-income-stocks-for-q2 | Sometimes, it may seem like growth and momentum investing is the way to go, but in the long run, a focus on value and income stocks is a winning strategy. Not all income stocks are necessarily attractive at a certain point - one should consider valuation before making an investment. | Top 10 Undervalued High-Yield Income Stocks For Q2 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-04-01 08:45:00 | https://www.prnewswire.com/news-releases/skinmedica-launches-neck-correct-cream-for-neck-and-decollete-301259926.html | IRVINE, Calif., April 1, 2021 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica ® Neck Correct Cream, the first product from the professional-grade skincare line formulated to address the specific biology of the skin on the neck and décolleté area. | SkinMedica® Launches Neck Correct Cream for Neck and Décolleté | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-04-01 08:31:00 | https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-24-week-results-from-phase-3-study-evaluating-rinvoq-upadacitinib-in-psoriatic-arthritis-301260638.html | NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately ... | New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-31 11:58:37 | https://seekingalpha.com/article/4417009-abbvie-plotting-course-to-revenue-growth-ex-humira-bull-case | AbbVie faces one of the toughest challenges in the pharmaceutical industry - the patent expiry of its $20bn-selling immunology drug Humira in 2023. Management provided detailed long-term revenue and financial guidance during its Feb earnings call illustrating how it will grow revenue long-term in spite of the LOE. | AbbVie: Plotting The Course To Revenue Growth Ex-Humira - The Bull Case | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-03-31 06:04:00 | https://www.fool.com/investing/2021/03/31/the-best-value-stock-to-buy-right-now/ | This stock has it all. | The Best Value Stock to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-30 12:06:50 | https://seekingalpha.com/article/4416784-collecting-abbvie-premium-ex-date-coming-up-for-this-5-percent-yielder | ABBV can be a bit volatile for most income investors, though they carry almost a 5% yield at this time. The company is undervalued, probably being discounted due to the reliance on Humira. | Collecting AbbVie Premium, Ex-Date Coming Up For This ~5% Yielder | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-03-30 10:23:32 | https://investorplace.com/2021/03/7-cannabis-stocks-that-offer-much-more-than-just-pot/ | You may be surprised that not all cannabis stocks are focused entirely on weed. Here are some diversified companies to consider. | 7 Cannabis Stocks That Offer Much More Than Just Pot | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-03-30 09:30:55 | https://www.benzinga.com/general/biotech/21/03/20400475/fda-accepts-abbvies-atogepant-us-review-application-for-migraine | The FDA has accepted for review AbbVie Inc's (NYSE: ABBV) marketing application seeking approval for Atogepant for the preventive treatment of migraine in adults who meet the criteria for episodic migraine. The regulatory decision is expected in late Q3 2021. | FDA Accepts AbbVie's Atogepant US Review Application For Migraine | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-03-29 18:55:22 | https://www.zacks.com/stock/news/1315125/abbvie-abbv-gains-as-market-dips-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $106.73, moving +0.71% from the previous trading session. | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-03-29 07:12:00 | https://www.fool.com/investing/2021/03/29/this-stalwarts-growth-story-isnt-over-yet/ | It's a big-name pharma with a storied history, but Eli Lilly still has plenty of room left to run. | This Stalwart's Growth Story Isn't Over Yet | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-27 17:02:10 | https://seekingalpha.com/article/4416435-91-top-dividend-stocks-on-earth-aprils-kiplinger-update | 91 'Top Dividend Stocks On Earth': April's Kiplinger Update | 91 'Top Dividend Stocks On Earth': April's Kiplinger Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Kiplinger | 2021-03-26 14:49:00 | https://www.kiplinger.com/investing/stocks/dividend-stocks/602509/big-pharmaceutical-stocks-bigger-income | Pharmaceutical stocks with stable, substantial dividends can hold their own in almost any environment, making them ideal for long-term income investors. | 7 Big Pharmaceutical Stocks for Bigger Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-03-26 12:53:17 | https://www.zacks.com/stock/news/1299453/this-is-why-abbvie-abbv-is-a-great-dividend-stock | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | This is Why AbbVie (ABBV) is a Great Dividend Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-26 10:15:00 | https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth | At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far. In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today. | Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-03-26 07:46:42 | https://247wallst.com/investing/2021/03/26/5-high-yielding-dividend-aristocrat-stocks-are-perfect-now-for-worried-investors/ | With March almost over, many investors are looking to the second quarter and beyond. | 5 High-Yielding Dividend Aristocrat Stocks Are Perfect Now for Worried Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-03-23 18:56:18 | https://www.zacks.com/stock/news/1285083/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know | AbbVie (ABBV) closed at $104.84 in the latest trading session, marking a -1% move from the prior day. | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-03-23 18:12:31 | https://www.gurufocus.com/news/1388062/abbvie-stock-shows-every-sign-of-being-fairly-valued | The stock of AbbVie (NYSE:ABBV, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. | AbbVie Stock Shows Every Sign Of Being Fairly Valued | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-03-22 14:33:48 | https://www.youtube.com/watch?v=jtAzqlrfkVA | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Roku, Lam Research, AbbVie & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Newsfile Corp | 2021-03-21 23:34:00 | https://www.newsfilecorp.com/release/78136/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-AbbVie-Inc.-ABBV | New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc.("AbbVie" or the "Company") (NYSE: ABBV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Ab... | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-03-19 16:42:44 | https://www.gurufocus.com/news/1387068/5-high-dividend-yield-stocks-broadly-bought-by-gurus | According to the High Dividend Yield Stocks page, a Premium feature of GuruFocus, five stocks with a dividend yield of at least 4% and double-digit guru buys over the past few months are AbbVie Inc. (NYSE:ABBV), Gilead Sciences Inc. (NASDAQ:GILD), Exxon Mobil Corp. (NYSE:XOM), Chevron Corp. (NYSE:CVX) and GlaxoSmithKli... | 5 High Dividend Yield Stocks Broadly Bought by Gurus | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-03-18 19:26:00 | https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-abbvie-inc---abbv-301250679.html | NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc.("AbbVie" or the "Company") (NYSE: ABBV). Such investors are advised to contact Robert S. | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-03-18 10:13:27 | https://www.zacks.com/stock/news/1281961/abbvie-abbv-down-as-fda-extends-review-of-rinvoq-snda | The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in active psoriatic arthritis by three months. | AbbVie (ABBV) Down as FDA Extends Review of Rinvoq sNDA | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-03-17 17:32:52 | https://investorplace.com/2021/03/4-top-stock-trades-for-thursday-abbv-tlt-pdd-five/ | AbbVie, the iShares 20+ Treasury Bond ETF, Pinduoduo and Five Below were our top stock trades for Thursday. Now, let's look at the charts. | 4 Top Stock Trades for Thursday: ABBV, TLT, PDD, FIVE | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2021-03-17 15:40:10 | https://www.forbes.com/sites/dividendchannel/2021/03/17/abbvie-shares-cross-5-yield-mark/ | In trading on Wednesday, shares of AbbVie were yielding above the 5% mark based on its quarterly dividend (annualized to $5.2), with the stock changing hands as low as $102.80 on the day. | AbbVie Shares Cross 5% Yield Mark | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-17 15:36:23 | https://seekingalpha.com/article/4414609-market-gives-you-discount-on-abbvie | AbbVie is down almost 6% after the FDA extends its review of one of its drugs. | Mr. Market Gives You A Discount On AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2021-03-17 12:04:48 | https://www.investors.com/news/technology/abbvie-stock-plunges-fda-delays-review-rinvoq-psoriatic-arthritis/ | AbbVie stock plunged Wednesday after the Food and Drug Administration requested additional information to assess the benefit of potential blockbuster drug Rinvoq in psoriatic arthritis. The post Did Pfizer Just Trip Up AbbVie's Chances For A New Arthritis Drug? | Did Pfizer Just Trip Up AbbVie's Chances For A New Arthritis Drug? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-03-17 11:39:57 | https://pulse2.com/abbv-stock-price-nyse-abbvie-fell-over-7-intraday-why-it-happened/ | The stock price of AbbVie Inc (NYSE: ABBV) fell by over 7% intraday. This is why it happened. | ABBV Stock Price Fell Over 7% Intraday: Why It Happened | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-03-17 08:45:00 | https://www.prnewswire.com/news-releases/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of-upadacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis-301248962.html | NORTH CHICAGO, Ill., March 17, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult... | AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-17 07:32:24 | https://seekingalpha.com/article/4414476-3-pharma-dividend-growth-stocks-yielding-4_5-percent | I discuss 3 large cap pharma stocks that are yielding about 4.5% or more and are undervalued based on P/E ratio. | 3 Pharma Dividend Growth Stocks Yielding 4.5% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-03-17 06:04:00 | https://www.fool.com/investing/2021/03/17/4-pharma-stocks-that-could-be-losers-with-the-19-t/ | An easily overlooked provision in the legislation could be bad news for four drugmakers, in particular. | 4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-16 15:43:53 | https://seekingalpha.com/article/4414342-connect-biopharma-pursues-150-million-u-s-ipo-plan | Connect Biopharma Pursues $150 Million U.S. IPO Plan | Connect Biopharma Pursues $150 Million U.S. IPO Plan | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Schaeffers Research | 2021-03-16 10:19:22 | https://www.schaeffersresearch.com/content/news/2021/03/16/abbvie-stock-inching-toward-highs-amid-drug-sale-talks | AbbVie Inc (NYSE:ABBV) is in the spotlight this morning, after news that the pharmaceutical company is in talks to sell a $5 billion portfolio of women's drugs. | AbbVie Stock Inching Toward Highs Amid Drug Sale Talks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-03-16 06:01:00 | https://www.fool.com/investing/2021/03/16/3-stocks-thatll-turn-your-1400-stimulus-check-into/ | Make money with your newfound cash with these three dividend stocks. | 3 Stocks That'll Turn Your $1,400 Stimulus Check Into a Money Machine | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-03-16 05:01:29 | https://investorplace.com/2021/03/7-blue-chip-stocks-with-strong-dividend-yields/ | Blue-chip stocks appeal to investors with their stability, consistent returns and dividend yield. In this article, we look at seven blue-chip stocks with strong dividends that could offer big returns. | 7 Blue-Chip Stocks With Strong Dividend Yields | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-03-15 18:31:35 | https://www.zacks.com/stock/news/1279609/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know | AbbVie (ABBV) closed at $110.26 in the latest trading session, marking a +1.89% move from the prior day. | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2021-03-15 16:50:00 | https://www.reuters.com/article/us-abbvie-womenshealth-exclusive/exclusive-abbvie-in-talks-to-sell-5-billion-womens-drugs-portfolio-sources-idUSKBN2B72P2 | U.S. drugmaker AbbVie Inc is holding talks to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters. | Exclusive: AbbVie in talks to sell $5 billion women's drugs portfolio - sources | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-03-15 09:58:39 | https://seekingalpha.com/article/4413947-sand-in-shoes-february-update | February was a fabulous month for equities as the S&P 500 rose 2.61% while small-cap and mid-cap names were up even more. | Sand In My Shoes - February Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-03-15 07:07:00 | https://www.fool.com/investing/2021/03/15/3-ways-to-become-a-millionaire-making-money-in-you/ | Boost your future financial security -- almost effortlessly! | 3 Ways to Become a Millionaire Making Money in Your Sleep | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.